Skip to main content Back to Top
Advertisement

5/3/2019

Dorzolamide Ophthalmic Solution

Products Affected - Description

    • Dorzolamide ophthalmic solution, Akorn, 2%, 10 mL bottle, 1 count, NDC 50383-0232-10
    • Dorzolamide ophthalmic solution, Teva, 2%, 10 mL bottle, 1 count, NDC 00591-2481-79 - discontinued
    • Dorzolamide ophthalmic solution, Teva, 2%, 10 mL bottle, 1 count, NDC 00093-7618-43 - discontinued

Reason for the Shortage

    • Akorn has dorzolamide ophthalmic solution on shortage due to manufacturing delays.
    • Merck did not provide a reason for the shortage.
    • Sandoz did not provide a reason for the shortage.
    • Teva discontinued dorzolamide ophthalmic solution in April 2018.
    • Bausch Health had dorzolamide ophthalmic solution on shortage due to manufacturing delays.

Available Products

    • Trusopt ophthalmic solution, Merck, 2%, 10 mL Ocumeter Plus bottle, 1 count, NDC 00006-3519-36
    • Dorzolamide ophthalmic solution, Bausch Health, 2%, 10 mL bottle, 1 count, NDC 24208-0485-10
    • Dorzolamide ophthalmic solution, Sandoz, 2%, 10 mL bottle, 1 count, NDC 61314-0019-10

Estimated Resupply Dates

    • Akorn has dorzolamide 2% ophthalmic solution in 10 mL bottles on allocation.

Updated

Updated May 3, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created October 30, 2017 by Benjamin Witt, PharmD, BCPS, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins